Johnson & Johnson (JNJ) and Pfizer (PFE) represent two distinct avenues for investing in the healthcare sector in 2026. Johnson & Johnson reported a 6% increase in fiscal 2025 sales, reaching $94.2 billion, with net income significantly boosted by a $7 billion reversal of its talc reserve. The company's Innovative Medicine and MedTech segments generated $60.4 billion and $33.8 billion in sales, respectively. Johnson & Johnson's debt-to-equity ratio stood at 0.59x, and it maintained a strong free cash flow of nearly $19.7 billion. The company raised its 2026 sales outlook to $100.8 billion to $101.4 billion and increased its quarterly dividend to $1.34 per share, marking its 64th consecutive annual increase.
Pfizer, on the other hand, reported a net loss of $248 million in the second quarter of 2026, primarily due to $4.3 billion in non-cash intangible asset impairments. The company's revenue for 2025 was $62.6 billion, down 1.6% from the previous year. Pfizer's debt-to-equity ratio was 0.75x, and its free cash flow was $9.1 billion, though it paid out $9.8 billion in dividends. The company anticipates a significant reduction in revenue due to patent and regulatory exclusivity expiries from 2026 through 2030. Pfizer's annual dividend yield of about 6% is well above Johnson & Johnson's roughly 2%.
Johnson & Johnson faces risks such as Medicare price negotiations for drugs like XARELTO and STELARA, and ongoing talc litigation, for which it proposed a $5.5 billion settlement. Pfizer's challenges include the loss of exclusivity on major products and the uncertainty surrounding its obesity programs from the recent acquisition of Metsera. Valuation-wise, Pfizer trades at lower multiples than Johnson & Johnson on both forward earnings and sales.
While Johnson & Johnson appears to be the better buy due to its diversified revenue streams and consistent performance, both stocks should be considered as part of a broader healthcare investment strategy. Pfizer's higher dividend yield may appeal to income investors, but its revenue challenges and impairments pose significant risks. Investors should plan to hold either stock for at least five years and continue adding to their positions regularly.